Equities research analysts expect that Adamis Pharmaceuticals Corp (NASDAQ:ADMP) will announce earnings of ($0.16) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Adamis Pharmaceuticals’ earnings, with estimates ranging from ($0.19) to ($0.09). Adamis Pharmaceuticals posted earnings of ($0.21) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 23.8%. The firm is scheduled to report its next earnings report on Monday, August 13th.
On average, analysts expect that Adamis Pharmaceuticals will report full-year earnings of ($0.69) per share for the current year, with EPS estimates ranging from ($0.81) to ($0.54). For the next year, analysts anticipate that the firm will post earnings of ($0.34) per share, with EPS estimates ranging from ($0.61) to $0.12. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow Adamis Pharmaceuticals.
Adamis Pharmaceuticals (NASDAQ:ADMP) last posted its earnings results on Friday, August 10th. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.10). The business had revenue of $3.92 million for the quarter, compared to analysts’ expectations of $4.14 million. Adamis Pharmaceuticals had a negative return on equity of 71.68% and a negative net margin of 207.24%.
ADMP stock remained flat at $$3.25 during trading on Friday. The company had a trading volume of 537,007 shares, compared to its average volume of 656,420. The stock has a market capitalization of $108.52 million, a PE ratio of -3.61 and a beta of 0.45. Adamis Pharmaceuticals has a 12-month low of $2.35 and a 12-month high of $5.85. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.57 and a current ratio of 1.88.
Several institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP purchased a new position in shares of Adamis Pharmaceuticals in the 1st quarter valued at approximately $244,000. Northern Trust Corp raised its position in shares of Adamis Pharmaceuticals by 50.7% in the 1st quarter. Northern Trust Corp now owns 139,536 shares of the specialty pharmaceutical company’s stock valued at $489,000 after purchasing an additional 46,924 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Adamis Pharmaceuticals by 1,050.3% in the 4th quarter. Wells Fargo & Company MN now owns 28,182 shares of the specialty pharmaceutical company’s stock valued at $124,000 after purchasing an additional 25,732 shares during the last quarter. Finally, BlackRock Inc. raised its position in shares of Adamis Pharmaceuticals by 7.7% in the 2nd quarter. BlackRock Inc. now owns 293,328 shares of the specialty pharmaceutical company’s stock valued at $939,000 after purchasing an additional 20,871 shares during the last quarter. Institutional investors and hedge funds own 10.72% of the company’s stock.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Featured Article: Price to Earnings Ratio (PE), For Valuing Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.